Generic Medicine Info
Indications and Dosage
Susceptible infections
Adult: 1-2 g daily in 2-4 divided doses. Max: 4 g daily.
Child: 25-50 mg/kg daily in 2-4 divided doses. For otitis media: 75-100 mg/kg daily in divided doses 6-12 hrly. Max: 4 g daily.

Susceptible infections
Adult: 2-4 g daily in 4 divided doses by deep IM or slow IV inj over 3-5 min or by IV infusion. Max: 8 g daily.
Child: 50-100 mg/kg daily in 4 divided doses. May increase to 200-300 mg/kg daily in severe infections.

Prophylaxis of surgical infections
Adult: 1-2 g given prior to surgery by IM or IV inj. Subsequent doses may be given as needed.
Renal Impairment
Patient on chronic, intermittent haemodialysis: 250 mg before the procedure, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.
CrCl (mL/min) Dosage
<5 250 mg 12 hrly.
5-20 250 mg 6 hrly.
>20 500 mg 6 hrly.
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
IM: Add 2 mL or 4 mL of sterile water for inj or NaCl 0.9% inj to 500 mg or 1 g vial, respectively. IV: Add 5 mL of sterile water for inj, dextrose 5% inj, NaCl 0.9% inj or other suitable soln to 500 mg vial. Shake well the entire soln.
Hypersensitivity to cefradine or to other cephalosporins.
Special Precautions
Hypersensitivity to penicillins. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Diarrhoea, nausea, glossitis, heartburn; fever, arthralgia, serum sickness-like reactions; rashes, toxic epidermal necrolysis, pruritus, urticaria, erythema multiforme, Stevens-Johnson syndrome; vaginitis, candidal overgrowth, candidiasis; eosinophilia, blood disorders (e.g. thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia, haemolytic anaemia); confusion, sleep disturbances; hyperactivity, hypertonia, dizziness, nervousness; liver enzyme disturbances, transient hepatitis, cholestatic jaundice; reversible interstitial nephritis, chest tightness; increased BUN and serum creatinine; pain on inj site (IM), thrombophlebitis (IV). Rarely, headache, vomiting, abdominal discomfort.
Potentially Fatal: Pseudomembranous colitis, anaphylaxis.
IM/IV/Parenteral/PO: B
Patient Counseling Information
This drug may cause dizziness which may impair ability to drive or operate machinery.
Drug Interactions
Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
Food Interaction
Food may delay the rate but does not affect the extent of absorption.
Lab Interference
False-positive urinary glucose test using Benedict's or Fehling's soln or Clinitest tablets.
Mechanism of Action: Cefradine is a 1st-generation cephalosporin which inhibits the final transpeptidation step of the peptidoglycan synthesis in bacterial cell wall by binding to 1 or more of the penicillin-binding proteins (PBPs), thus arresting cell wall synthesis leading to bacterial cell death.
Absorption: Rapidly and almost completely absorbed from the GI tract. Food may delay the rate but does not affect the extent of absorption. Time to peak plasma concentration: 1 hr (oral); w/in 1-2 hr (IM).
Distribution: Widely distributed to body tissues and fluids; CSF (insignificant amount). Crosses the placenta and enters breast milk (small amount). Plasma protein binding: Approx 8-12%.
Excretion: Via urine (oral: >90%; IM: 60-80%) as unchanged drug. Plasma half-life: Approx 1 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Cephradine, CID=38103, https://pubchem.ncbi.nlm.nih.gov/compound/Cephradine (accessed on Jan. 21, 2020)

Store below 25°C.
MIMS Class
ATC Classification
J01DB09 - cefradine ; Belongs to the class of first-generation cephalosporins. Used in the systemic treatment of infections.
Buckingham R (ed). Cefradine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/10/2014.

Disclaimer: This information is independently developed by MIMS based on Cefradine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in